Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 3/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14154245 | 0.90 | MTNR1A (0.56) | ALDH1A1POLBHTTCCR2KMT2A | |
| SCHEMBL30229439 | 0.85 | P2RX4 (0.53) | ALDH1A1POLBHTTCCR2KMT2A | |
| SCHEMBL18247571 | 0.85 | P2RX4 (0.53) | ALDH1A1POLBHTTCCR2KMT2A | |
| SCHEMBL4055635 | 0.84 | GRIK1 (0.46) | ALDH1A1POLBHTTCCR2GRIK1 | |
| SCHEMBL28263362 | 0.84 | CCR2 (0.43) | ALDH1A1POLBHTTCCR2GRIK1 | |
| SCHEMBL27862731 | 0.82 | LMNA (0.53) | ALDH1A1POLBHTTCCR2KMT2A | |
| SCHEMBL30229786 | 0.82 | CCR2 (0.48) | ALDH1A1CCR2TSHR | |
| SCHEMBL20853333 | 0.82 | CCR2 (0.48) | ALDH1A1CCR2TSHR | |
| SCHEMBL10444001 | 0.81 | ALDH1A1 (0.55) | ALDH1A1POLBHTTCCR2GRIK1 | |
| SCHEMBL18002356 | 0.81 | CCR2 (0.52) | ALDH1A1CCR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | ALDH1A1 952/4885POLB 2321/4885HTT 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.